A) For what condition did the FDA approve this drug? B) How many aromatic rings does this drug contain? C) How many "true" lone pairs does this drug contain? D) How many aromatic pi electrons does this drug contain?

Chemistry by OpenStax (2015-05-04)
1st Edition
ISBN:9781938168390
Author:Klaus Theopold, Richard H Langley, Paul Flowers, William R. Robinson, Mark Blaser
Publisher:Klaus Theopold, Richard H Langley, Paul Flowers, William R. Robinson, Mark Blaser
Chapter5: Thermochemistry
Section: Chapter Questions
Problem 52E: Before the introduction of chlorofluorocarbons, sulfur dioxide (enthalpy of vaporization, 6.00...
icon
Related questions
icon
Concept explainers
Question
NH₂
Imbruvica
ABBVIE WINS
PHARMACYCLICS
PHARMACEUTICALS: $21 billion
deal helps firm become a leader
in treating blood cancers
UST MONTHS AFTER abandoning its $54 bil-
lion bid for specialty drug maker Shire, AbbVie
is shelling out $21 billion for Sunnyvale, Calif.
based Pharmacyclics. The purchase furthers AbbVie's
ambitions in the field of hematological cancer and re-
duces its reliance on one major product.
The hefty price tag is the result of heated competi-
tion. "I've been through a lot of these, and I'd say this is
one of the most competitive ones I've seen." AbbVie's
CEO Richard A. Gonzalez said on a March 5 call with
investors. Three companies were bidding against each
other until the bitter end, he said. Indeed, just hours
before the deal was announced, some media outlets re
ported that Johnson & Johnson had won out.
Pharmacyclics's key asset is Imbruvica, a BTK inhibi-
tor acquired in 2006 from Celera Genomics for just
6
$2 million and some equity. FDA approved Imbravica
in late 2013 to treat mantle cell leukemia, and the drug
has since won the agency's nod in three other blood
cancers. It is expected to bring in $1 billion in sales this
year for Pharmacyclics and its marketing partner J&J.
Imbruvica represents "a pipeline in a molecule,
much like Humira did," Gonzalez said. AbbVie's Humi-
ra is the world's top-selling drug, bringing in $12.5 bil-
lion in sales last year across a range of inflammatory
diseases, but its patent is set to expire in late 2016.
AbbVie believes its portion of peak sales for Imbruvica
could exceed $7 billion per year.
The deal also advances AbbVie's goal of becom-
ing a powerhouse in treating hematological cancer, a
market worth $24 billion in 2014. AbbVie sees syner-
gies between Imbruvica and two small molecules in its
pipeline: ABT-199, which blocks Bel-a and is in Phase
Il studies to treat acute myelogenous leukemia and
duvelisib, a PI3K inhibitor in Phase II studies to treat
several blood cancers.
Last October, AbbVie walked away from the Shire
deal after a change in U.S. tax law. Gonzalez said the
two deals are strategically "very different." Shire was
viewed as an avenue to lowering AbbVie's tax base,
whereas Pharmacyclics complements its oncology
portfolio LISA JARVIS
Transcribed Image Text:NH₂ Imbruvica ABBVIE WINS PHARMACYCLICS PHARMACEUTICALS: $21 billion deal helps firm become a leader in treating blood cancers UST MONTHS AFTER abandoning its $54 bil- lion bid for specialty drug maker Shire, AbbVie is shelling out $21 billion for Sunnyvale, Calif. based Pharmacyclics. The purchase furthers AbbVie's ambitions in the field of hematological cancer and re- duces its reliance on one major product. The hefty price tag is the result of heated competi- tion. "I've been through a lot of these, and I'd say this is one of the most competitive ones I've seen." AbbVie's CEO Richard A. Gonzalez said on a March 5 call with investors. Three companies were bidding against each other until the bitter end, he said. Indeed, just hours before the deal was announced, some media outlets re ported that Johnson & Johnson had won out. Pharmacyclics's key asset is Imbruvica, a BTK inhibi- tor acquired in 2006 from Celera Genomics for just 6 $2 million and some equity. FDA approved Imbravica in late 2013 to treat mantle cell leukemia, and the drug has since won the agency's nod in three other blood cancers. It is expected to bring in $1 billion in sales this year for Pharmacyclics and its marketing partner J&J. Imbruvica represents "a pipeline in a molecule, much like Humira did," Gonzalez said. AbbVie's Humi- ra is the world's top-selling drug, bringing in $12.5 bil- lion in sales last year across a range of inflammatory diseases, but its patent is set to expire in late 2016. AbbVie believes its portion of peak sales for Imbruvica could exceed $7 billion per year. The deal also advances AbbVie's goal of becom- ing a powerhouse in treating hematological cancer, a market worth $24 billion in 2014. AbbVie sees syner- gies between Imbruvica and two small molecules in its pipeline: ABT-199, which blocks Bel-a and is in Phase Il studies to treat acute myelogenous leukemia and duvelisib, a PI3K inhibitor in Phase II studies to treat several blood cancers. Last October, AbbVie walked away from the Shire deal after a change in U.S. tax law. Gonzalez said the two deals are strategically "very different." Shire was viewed as an avenue to lowering AbbVie's tax base, whereas Pharmacyclics complements its oncology portfolio LISA JARVIS
A) For what condition did the FDA approve this drug?
B) How many aromatic rings does this drug contain?
C) How many "true" lone pairs does this drug contain?
D) How many aromatic pi electrons does this drug contain?
Transcribed Image Text:A) For what condition did the FDA approve this drug? B) How many aromatic rings does this drug contain? C) How many "true" lone pairs does this drug contain? D) How many aromatic pi electrons does this drug contain?
Expert Solution
steps

Step by step

Solved in 4 steps

Blurred answer
Knowledge Booster
Reactive Intermediates
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, chemistry and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Chemistry by OpenStax (2015-05-04)
Chemistry by OpenStax (2015-05-04)
Chemistry
ISBN:
9781938168390
Author:
Klaus Theopold, Richard H Langley, Paul Flowers, William R. Robinson, Mark Blaser
Publisher:
OpenStax